Methods for the systematic investigation of gastrointestinal contrast media for MRI: evaluation of intestinal distribution by radiographic monitoring.
Comparison of the effectiveness of various gastrointestinal (GI) contrast agents for magnetic resonance (MR) imaging is often complicated by varying amounts intraluminal filling with the orally administered agents. To achieve more uniform and reproducible imaging results with GI contrast agents for MR imaging (GICMR), we evaluated a radiographic method for monitoring intraluminal filling and distribution. Solutions of Mn-DPDP (2 mM), to which a small amount of barium sulfate (6 wt/vol%) was added, were administered orally to dogs. Gastric emptying and small bowel transit were monitored fluoroscopically. MR imaging was performed either 1) at a fixed time after administration of the contrast agent or 2) at a variable interval when the contrast agent was observed fluoroscopically to be in the terminal ileum. When initiation of MR imaging was guided by fluoroscopic monitoring of intestinal contrast distribution, uniform and reproducible intestinal contrast enhancement by GICMR was achieved. However, when MR imaging was performed at a fixed time interval after oral administration, non-uniform and variable GI visualization was obtained, and this corresponded to the variable intestinal distribution observed fluoroscopically. We conclude that reproducible intestinal filling with orally administered contrast agents can be accomplished with a radiographic monitoring technique, and this promotes more consistent GI visualization on MR images. Such standardized and reproducible methods are necessary for studies in which the effectiveness of GI contrast media for MR imaging is evaluated and compared.
Rubin
D L
DL
Department of Diagnostic Radiology and Nuclear Medicine, Stanford University Medical Center, California 94305.
Muller
H H
HH
Young
S W
SW
D000284:Administration, Oral; D000818:Animals; D003287:Contrast Media / Q000008:administration & dosage; D004064:Digestive System / Q000033:anatomy & histology* / Q000000981:diagnostic imaging; D004285:Dogs; D004492:Edetic Acid / Q000008:administration & dosage / Q000031:analogs & derivatives; D005471:Fluoroscopy; D005772:Gastrointestinal Transit; D008279:Magnetic Resonance Imaging; D011732:Pyridoxal Phosphate / Q000008:administration & dosage / Q000031:analogs & derivatives*
D003287:Contrast Media; D011732:Pyridoxal Phosphate; D004492:Edetic Acid; C060076:N,N'-bis(pyridoxal-5-phosphate)ethylenediamine-N,N'-diacetic acid